Project title:

Using in vivo modelling to investigate therapeutic approaches to reverse/prevent disease resistance in children with high-risk Ph-like B-ALL and T-ALL treated with targeted therapies

Chief Investigator:

Dr Laura Eadie

Funding Amount:





Relapsed acute lymphoblastic leukaemia (ALL) is the leading cause of childhood non-traumatic death (15% of T-ALL and 20% of B-ALL patients relapse). Chemotherapy results in adverse side effects and a lifelong risk of other malignancies. Risk stratification and targeted therapy based on the molecular genetics of an individual’s disease is warranted. We will test the efficacy of novel drugs and combination therapies in mouse models of ALL. Findings will inform clinical practice; therapeutic strategies will be optimised to ensure the best chance of cure for children with high-risk forms of ALL.

Review Research Outcomes

Start typing and press Enter to search